Journal of Thermal Analysis and Calorimetry

Autor: Gomes, Elionai Cassiana de Lima, Oliveira, M. A., Mussel, W. N., Castro, W. V., Soares, C. D. V.
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Zdroj: Repositório Institucional da UFBA
Universidade Federal da Bahia (UFBA)
instacron:UFBA
DOI: 10.1007/s10973-011-1510-0
Popis: texto completo: acesso restrito. p. 657–664. Submitted by Ana Valéria de Jesus Moura (anavaleria_131@hotmail.com) on 2012-02-25T22:21:54Z No. of bitstreams: 1 Thermal characterization of lovastatin in pharmaceutical formulations.pdf: 994762 bytes, checksum: dfe0bc17d521cc207dfd6b3de4a888d3 (MD5) Made available in DSpace on 2012-02-25T22:21:54Z (GMT). No. of bitstreams: 1 Thermal characterization of lovastatin in pharmaceutical formulations.pdf: 994762 bytes, checksum: dfe0bc17d521cc207dfd6b3de4a888d3 (MD5) Previous issue date: 2011 Thermogravimetry (TG) and differential scanning calorimetry (DSC) are useful techniques that have been successfully applied in the pharmaceutical industry to reveal important information regarding the physicochemical properties of drug and excipient molecules such as polymorphism, stability, purity, and formulation compatibility among others. In this study, lovastatin was studied by TG, DSC, and other techniques such as Fourier transform infrared spectroscopy, optical microscopy, X-ray diffraction, chromatography, and mass spectrometry. Lovastatin showed melting point at 445 K and thermal stability up to 535 K. It presented morphological polymorphism, which in the drug has the same unit cell, but with different crystal habits. Preservative excipient butylhydroxyanisole (BHA) causes amorphization of lovastatin crystallites and, therefore is incompatible with lovastatin. Degradation by hydrolysis was observed under neutral, acid, and basic conditions. The active degradation product, lovastatin hydroxyacid, was obtained after neutral and basic hydrolysis.
Databáze: OpenAIRE